GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Osi Pharmaceuticals Inc. (OSIP) [hlAlert]

Rating:
Hold OSIP

Osi Pharmaceuticals Inc. (OSIP) downgraded to Neutral by UBS

Posted on: Tuesday,  Mar 2, 2010  8:25 AM ET by UBS

Osi Pharmaceuticals Inc.
(NASDAQ: OSIP) downgraded to Neutral by UBS.

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/2/2010 8:25 AM Hold
None
56.56
as of 12/31/2010
1 Week   
1 Month   
3 Months   
1 YTD up  82.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/30/2009 12:25 PM Buy
None
33.57 46.00
7/24/2008 10:25 AM Buy
None
49.40 58.00
1/4/2008 9:25 AM Buy
None
44.80 57.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy